The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Recombinant Therapeutic Antibodies and Proteins-Global Market Insights and Sales Trends 2024
Synopsis
Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.
The global Recombinant Therapeutic Antibodies and Proteins market size is expected to reach US$ 143680 million by 2029, growing at a CAGR of 6.9% from 2023 to 2029. The market is mainly driven by the significant applications of Recombinant Therapeutic Antibodies and Proteins in various end use industries. The expanding demands from the Oncology, Hematology, Immunology and Endocrinology, are propelling Recombinant Therapeutic Antibodies and Proteins market. Plasma Protein, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Fusion Proteins segment is estimated at % CAGR for the next seven-year period.
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 92.5 billion in 2017, and is expected to witness a robust CAGR of 11.2% over the forecast period (2017 – 2025).
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Recombinant Therapeutic Antibodies and Proteins, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Recombinant Therapeutic Antibodies and Proteins market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Recombinant Therapeutic Antibodies and Proteins market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Recombinant Therapeutic Antibodies and Proteins sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Recombinant Therapeutic Antibodies and Proteins covered in this report include Abbott, Amgen, Biogen, Eli Lilly, Roche, Johnson and Johnson, Merck, Novo Nordisk and Pfizer, etc.
The global Recombinant Therapeutic Antibodies and Proteins market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott
Amgen
Biogen
Eli Lilly
Roche
Johnson and Johnson
Merck
Novo Nordisk
Pfizer
Sanofi
Global Recombinant Therapeutic Antibodies and Proteins market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Recombinant Therapeutic Antibodies and Proteins market, Segment by Type:
Plasma Protein
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others
Global Recombinant Therapeutic Antibodies and Proteins market, by Application
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Recombinant Therapeutic Antibodies and Proteins companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.
The global Recombinant Therapeutic Antibodies and Proteins market size is expected to reach US$ 143680 million by 2029, growing at a CAGR of 6.9% from 2023 to 2029. The market is mainly driven by the significant applications of Recombinant Therapeutic Antibodies and Proteins in various end use industries. The expanding demands from the Oncology, Hematology, Immunology and Endocrinology, are propelling Recombinant Therapeutic Antibodies and Proteins market. Plasma Protein, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Fusion Proteins segment is estimated at % CAGR for the next seven-year period.
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 92.5 billion in 2017, and is expected to witness a robust CAGR of 11.2% over the forecast period (2017 – 2025).
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Recombinant Therapeutic Antibodies and Proteins, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Recombinant Therapeutic Antibodies and Proteins market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Recombinant Therapeutic Antibodies and Proteins market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Recombinant Therapeutic Antibodies and Proteins sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Recombinant Therapeutic Antibodies and Proteins covered in this report include Abbott, Amgen, Biogen, Eli Lilly, Roche, Johnson and Johnson, Merck, Novo Nordisk and Pfizer, etc.
The global Recombinant Therapeutic Antibodies and Proteins market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott
Amgen
Biogen
Eli Lilly
Roche
Johnson and Johnson
Merck
Novo Nordisk
Pfizer
Sanofi
Global Recombinant Therapeutic Antibodies and Proteins market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Recombinant Therapeutic Antibodies and Proteins market, Segment by Type:
Plasma Protein
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others
Global Recombinant Therapeutic Antibodies and Proteins market, by Application
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Recombinant Therapeutic Antibodies and Proteins companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Recombinant Therapeutic Antibodies and Proteins
1.1 Recombinant Therapeutic Antibodies and Proteins Market Overview
1.1.1 Recombinant Therapeutic Antibodies and Proteins Product Scope
1.1.2 Recombinant Therapeutic Antibodies and Proteins Market Status and Outlook
1.2 Global Recombinant Therapeutic Antibodies and Proteins Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2018-2029)
1.4 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Region (2018-2023)
1.5 Global Recombinant Therapeutic Antibodies and Proteins Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Recombinant Therapeutic Antibodies and Proteins Market Size (2018-2029)
1.6.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size (2018-2029)
1.6.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Size (2018-2029)
1.6.3 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size (2018-2029)
1.6.4 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size (2018-2029)
1.6.5 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size (2018-2029)
2 Recombinant Therapeutic Antibodies and Proteins Market by Type
2.1 Introduction
2.1.1 Plasma Protein
2.1.2 Fusion Proteins
2.1.3 Monoclonal Antibodies
2.1.4 Hormones
2.1.5 Enzyme
2.1.6 Coagulation Factors
2.1.7 Others
2.2 Global Recombinant Therapeutic Antibodies and Proteins Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Type (2018-2023)
2.2.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Recombinant Therapeutic Antibodies and Proteins Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Recombinant Therapeutic Antibodies and Proteins Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Recombinant Therapeutic Antibodies and Proteins Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Recombinant Therapeutic Antibodies and Proteins Revenue Breakdown by Type (2018-2029)
3 Recombinant Therapeutic Antibodies and Proteins Market Overview by Application
3.1 Introduction
3.1.1 Oncology
3.1.2 Hematology
3.1.3 Immunology
3.1.4 Endocrinology
3.1.5 Infectious Disease
3.1.6 Cardiovascular Disease
3.1.7 Others
3.2 Global Recombinant Therapeutic Antibodies and Proteins Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Application (2018-2023)
3.2.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Recombinant Therapeutic Antibodies and Proteins Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Recombinant Therapeutic Antibodies and Proteins Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Recombinant Therapeutic Antibodies and Proteins Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Recombinant Therapeutic Antibodies and Proteins Revenue Breakdown by Application (2018-2029)
4 Recombinant Therapeutic Antibodies and Proteins Competition Analysis by Players
4.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Recombinant Therapeutic Antibodies and Proteins as of 2022)
4.3 Date of Key Players Enter into Recombinant Therapeutic Antibodies and Proteins Market
4.4 Global Top Players Recombinant Therapeutic Antibodies and Proteins Headquarters and Area Served
4.5 Key Players Recombinant Therapeutic Antibodies and Proteins Product Solution and Service
4.6 Competitive Status
4.6.1 Recombinant Therapeutic Antibodies and Proteins Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Abbott
5.1.1 Abbott Profile
5.1.2 Abbott Main Business
5.1.3 Abbott Recombinant Therapeutic Antibodies and Proteins Products, Services and Solutions
5.1.4 Abbott Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) & (2018-2023)
5.1.5 Abbott Recent Developments
5.2 Amgen
5.2.1 Amgen Profile
5.2.2 Amgen Main Business
5.2.3 Amgen Recombinant Therapeutic Antibodies and Proteins Products, Services and Solutions
5.2.4 Amgen Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) & (2018-2023)
5.2.5 Amgen Recent Developments
5.3 Biogen
5.3.1 Biogen Profile
5.3.2 Biogen Main Business
5.3.3 Biogen Recombinant Therapeutic Antibodies and Proteins Products, Services and Solutions
5.3.4 Biogen Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) & (2018-2023)
5.3.5 Eli Lilly Recent Developments
5.4 Eli Lilly
5.4.1 Eli Lilly Profile
5.4.2 Eli Lilly Main Business
5.4.3 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Products, Services and Solutions
5.4.4 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) & (2018-2023)
5.4.5 Eli Lilly Recent Developments
5.5 Roche
5.5.1 Roche Profile
5.5.2 Roche Main Business
5.5.3 Roche Recombinant Therapeutic Antibodies and Proteins Products, Services and Solutions
5.5.4 Roche Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) & (2018-2023)
5.5.5 Roche Recent Developments
5.6 Johnson and Johnson
5.6.1 Johnson and Johnson Profile
5.6.2 Johnson and Johnson Main Business
5.6.3 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Products, Services and Solutions
5.6.4 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) & (2018-2023)
5.6.5 Johnson and Johnson Recent Developments
5.7 Merck
5.7.1 Merck Profile
5.7.2 Merck Main Business
5.7.3 Merck Recombinant Therapeutic Antibodies and Proteins Products, Services and Solutions
5.7.4 Merck Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) & (2018-2023)
5.7.5 Merck Recent Developments
5.8 Novo Nordisk
5.8.1 Novo Nordisk Profile
5.8.2 Novo Nordisk Main Business
5.8.3 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Products, Services and Solutions
5.8.4 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) & (2018-2023)
5.8.5 Novo Nordisk Recent Developments
5.9 Pfizer
5.9.1 Pfizer Profile
5.9.2 Pfizer Main Business
5.9.3 Pfizer Recombinant Therapeutic Antibodies and Proteins Products, Services and Solutions
5.9.4 Pfizer Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) & (2018-2023)
5.9.5 Pfizer Recent Developments
5.10 Sanofi
5.10.1 Sanofi Profile
5.10.2 Sanofi Main Business
5.10.3 Sanofi Recombinant Therapeutic Antibodies and Proteins Products, Services and Solutions
5.10.4 Sanofi Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) & (2018-2023)
5.10.5 Sanofi Recent Developments
6 North America
6.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Recombinant Therapeutic Antibodies and Proteins Market Dynamics
11.1 Recombinant Therapeutic Antibodies and Proteins Industry Trends
11.2 Recombinant Therapeutic Antibodies and Proteins Market Drivers
11.3 Recombinant Therapeutic Antibodies and Proteins Market Challenges
11.4 Recombinant Therapeutic Antibodies and Proteins Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
